1-3 of 3
Susan J. McCall, MSN ANP-BC
Close
Sort by
Journal Articles

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

Craig S. Sauter, MD, Stephanie L. Verwys, Susan J. McCall, MSN ANP-BC, Shoshana T. Miller, Amanda I. Courtien, Heiko Schoder, MD, Pamela Harris, MD, Matthew J. Matasar, MD MS, Anas Younes, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2016) 128 (22): 4198.
https://doi.org/10.1182/blood.V128.22.4198.4198
Published: 2016
Journal Articles

Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation

Gunjan L Shah, MDMS, Kurt S Bantilan, MPH, Stephanie L Verwys, BS, Susan J McCall, MSN ANP-BC, Joachim Yahalom, MD, Matthew J. Matasar, MD MS, Alison J Moskowitz, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 520.
https://doi.org/10.1182/blood.V126.23.520.520
Published: 2015
Journal Articles

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Alison J Moskowitz, MD, Sun Cho, Martin Fleisher, PhD, Kaitlin M Woo, MS, Zhigang Zhang, PhD, Stephanie Fox, Susan J McCall, MSN ANP-BC, Heiko Schoder, MD, Joachim Yahalom, MD, Craig H Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 180.
https://doi.org/10.1182/blood.V126.23.180.180
Published: 2015